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ABSTRACT 
Introduction: Recent work suggests that wearables can augment conventional measures of Parkinson's disease 
(PD). We evaluated the relationship between conventional measures of disease and motor severity (e.g., MDS-
UPDRS part III), laboratory-based measures of gait and balance, and daily-living physical activity measures in 
patients with PD. 
Methods: Data from 125 patients (age: 71.7±6.5 years, Hoehn and Yahr: 1-3, 60.5% men) were analyzed. The 
MDS-UPDRS-part III was used as the gold standard of motor symptom severity. Gait and balance were 
quantified in the laboratory. Daily-living gait and physical activity metrics were extracted from an accelerometer 
worn on the lower back for 7 days.  
 
Results: In multivariate analyses, daily-living physical activity and gait metrics, laboratory-based balance, 
demographics and subject characteristics together explained 46% of the variance in MDS-UPDRS-part III 
scores. Daily-living measures accounted for 62% of the explained variance, laboratory measures 30%, and 
demographics and subject characteristics 7% of the explained variance. Conversely, demographics and subject 
characteristics, laboratory-based measures of gait symmetry, and motor symptom severity together explained 
less than 30% of the variance in total daily-living physical activity. MDS-UPDRS-part III scores accounted for 
13% of the explained variance, i.e., <4% of all the variance in total daily-living activity. 
  
Conclusions:  Our findings suggest that conventional measures of motor symptom severity do not strongly 
reflect daily-living activity and that daily-living measures apparently provide important information that is not 
captured in a conventional one-time, laboratory assessment of gait, balance or the MDS-UPDRS. To provide a 
more complete evaluation, wearable devices should be considered.  
 
Key words: Parkinson’s disease, wearable device, accelerometers, inertial measurement units, digital health, 
daily-living activity  
INTRODUCTION 
Difficulties in gait, balance, and mobility are major contributors to disability, diminished quality of life and fall 
risk in patients with Parkinson disease's (PD). In the past, these symptoms have generally been quantified in the 
laboratory and in clinical settings. Emerging evidence suggests that there are key differences between gait 
measured in the clinic or laboratory setting versus measures assessed during daily-living[1-4]. Furthermore, 
measures based on community ambulation apparently may help to predict important outcomes such as fall 
risk[5,6] and quality of life[7]. These findings support the idea that the assessment of mobility during daily-
living provides information that is complementary to more conventional clinic and laboratory assessments of 
gait and motor function.  
 
Several recent studies used wearable sensors to characterize and quantify daily-living physical activity among 
patients with PD[8-13]. Not surprisingly, the results of these studies suggest that everyday mobility differs in 
people with PD, as compared with age-matched controls, and that daily-living activity measures have utility in 
assessing and tracking PD by reflecting the subject's movement at home and in the community. Since activity 
and every-day function may be influenced by factors such as cognitive function, affect, environment, and social 
interactions, measures of daily-living may capture features that are not reflected in a single test in a laboratory 
or clinical setting. However, it has not been fully explored if and how the quality and quantity of daily-life 
physical activity characteristics relate to the conventional assessment of motor symptom severity in PD. 
 
The assessment of disease severity is routinely conducted in the clinic using the Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS)[14]. The motor section subscale of the MDS-UPDRS (part III) evaluates motor 
symptom severity and is often used as the primary outcome for clinical studies in PD. It is widely accepted that 
gait performance, when measured in the clinic, correlates with disease severity[15]. It is also well-established 
that daily-living physical activity is related to morbidity and mortality and that it may positively modify disease 
severity, improving a wide range of global and specific motor and non-motor symptom in PD[16-18]. 
Nonetheless, the relationships between the severity of the motor symptoms in PD, gait, and balance, as measured 
during a one-time visit to the clinic, and measures based on daily-living mobility are not clearly understood.   
 
One could speculate that people with more severe motor symptoms are less active. However, since activity may 
be affected by more than just motor symptoms and abilities, this relationship may be more complex. Several 
studies found associations between some items of the UPDRS-part III with sensor-derived gait acceleration in 
PD patients[19-21]. Yet, those studies did not explore the motor severity–daily-living physical activity 
relationship considering gait and balance assessed in the laboratory setting. Therefore, in the present analysis, 
we evaluated the relationship between PD motor symptom severity and metrics based on the laboratory-based 
assessment of mobility, on the one hand, and the daily-living assessment of mobility, on the other. In addition, 
since total daily-living physical activity is associated with many positive and negative health care outcomes 
(e.g., dementia, mortality) and since its benefits are well established[22,23], we investigated the relationship 
between total daily-living physical activity (based on objective ambulatory monitoring), clinic-based 
assessment of disease severity (MDS-UPDRS part I-III) and clinic-based metrics of mobility (gait and balance). 
 
METHODS 
Participants  
The present analysis is based on the baseline assessment of subjects who participated in a randomized controlled 
trial designed to reduce fall rates in older adults, as detailed previously[24]. Briefly, the study was conducted at 
5 clinical centers (Belgium, Israel, Italy, the Netherlands, and United Kingdom). The inclusion criteria for the 
present analyses were:  (a) People diagnosed with PD according to the UK Brain Bank criteria by a movement 
disorders specialist (b) age 60-90 years, (c) Hoehn and Yahr stage I-III, (d) taking anti-parkinsonian medications 
and with stable prescriptions at least for the past month, (e) had at least two falls in the 6 months prior to 
assessment, and (f) able to walk at least 5 minutes without assistance and (f) physical activity recording times 
greater than 3 days. Subjects were excluded if they had other significant comorbidities, clinical diagnosis of 
dementia or severe cognitive impairment (Mini Mental State Exam score, MMSE<21). The study was approved 
by each clinical site’s ethics committee. All participants provided informed written consent prior to testing. 
 
Assessment of demographics and other subject characteristics   
Age, gender, and other subject characteristics were collected. Motor symptom severity was assessed using the 
motor part of the MDS-UPDRS, i.e., part III[14] in a self-reported ON stage. Parts I and II of the MDS-UPDRS 
evaluated motor and non-motor experiences of daily-living based on-self-report.  
 
Laboratory-based assessment of mobility 
The participants walked back and forth in a well-lit corridor of 15 meters for one minute at a preferred, usual 
walking pace. Gait measures (e.g., speed, step length, and stride time variability) were collected using a Zeno 
instrumented walkway and PKMAS software, (Havertown, PA, USA)[25] and an inertial measurement unit 
placed on the lower back (Opal, APDM, Portland, OR, USA). Only straight-line walks, defined as sagittal 
progression walking, were analyzed. To compare laboratory to daily-living gait, only acceleration-based 
features were calculated from the inertial measurement unit. To further assess balance, the Mini-Balance 
Evaluation Systems Test (Mini-BESTest) and the Four Square Step Test were used. Endurance was evaluated 
using the Two Minute Walk Test by measuring the total distance covered[26].   
 
Daily-living assessment of physical activity 
At the end of the laboratory testing session, a small, light-weight, water-proof, tri-axial accelerometer (Axivity 
AX3, York, UK; 23.0×32.5×7.6 mm; weight: 11 grams; 100 Hz sampling rate) was placed on each subject's 
lower back at the level of the fifth lumbar vertebrae, as previously described[11] . The device was attached with 
a hydrogel adhesive and covered with a Hypafix bandage. Participants were asked to wear the device 
continuously for one week and to continue their daily activities as usual. Upon completion of the one-week 
recording, participants removed the device and sent it back to the local clinical site.  
 
Daily-living activity metrics 
As previously described [9], an algorithm automatically identified the different activities (walking, lying, 
standing, and sitting) and each bout of walking throughout the week-long recording and then extracted measures 
that reflect the quantity and quality of walking. To focus on steady-state walking and to compare in-lab walking 
with community ambulation, we evaluated walking bouts that were at least 60 seconds long[9]. However, when 
focusing on gait quantity, we used walking bouts of all lengths. The extracted measures are defined in 
Supplementary Material Table 1; these include measures of gait quantity (e.g., number of steps, number of 
walking bouts) and gait quality. Gait quality measures included those that reflect pace (e.g., step length), gait 
symmetry (e.g., .step regularity) gait variability (e.g., the amplitude of dominant frequency) and variability 
across walking bouts (e.g., SD of the peaks amplitude CV). To describe the overall level and distribution of 
physical activity intensity, we averaged the vector magnitude value over fifteen-second epoch, similar to 
Doherty et al [27]. Then, we generated the signal vector magnitude, SVM, measurement, an empirical 
cumulative distribution function from all available fifteen-second epochs (for further information on how SVM 
reflects daily-living physical activity, see Supplementary Material Methods). Data was included in the analysis 
if the recording was longer than three days. 
 
Statistical Analyses 
A series of multivariable linear regression analyses were performed to identify independent predictors 
associated with the two dependent measures of interest: 1) motor symptom severity as expressed by the MDS-
UPDRS-part III; and, in separate analyses, 2) total daily-living physical activity level, as expressed by the SVM 
of the acceleration signal, summed over the week. Normality of data was assessed using Shapiro-Wilk tests. To 
avoid colinearity, we first examined the relationships among metrics within daily-living and within laboratory 
subcategories using Pearson's correlations. If two metrics were strongly correlated with one another (r>0.7), 
only the one most strongly associated with the dependent variable (e.g., MDS-UPDRS-part III) was retained. 
Subsequently, we carried out a series of backward regression models to identify the relationship between the 
dependent outcome and independent factors associated with the dependent variable by examining each family 
of measures first (e.g., balance and functional tests, gait quantity, gait pace, gait symmetry, gait variability, day 
and night activity, and variability across walking bouts, demographics and subject's characteristics and MDS-
UPDRS I-III) and then generating a single, parsimonious model. The process is summarized in Supplementary 
Material Figure 1. A variable was entered into the model if the significance level of its F value of the ANOVA  
was less than 0.05 and was removed if the significance level is greater than 0.10. All analyses were adjusted for 
age, sex and disease duration. All of the independent predictors that were identified within each set were then 
entered into another backward regression model to identify the laboratory and daily-living predictors. Finally, 
the predictors that remained in those models were entered into a final regression model. We report the beta and 
p-values for the predictors. SPSS version 24 was used for the statistical analyses.    
 
RESULTS 
The subjects had moderate disease severity (Hoehn & Yahr 1-3) and were multiple fallers (at least two falls in 
6 months prior to assessment). They were generally well-educated, did not have major cognitive impairments, 
and had approximately 10 years of motor symptoms (Table 1). The univariate relationships between the MDS-
UPDRS-parts I-III (and the total score), two selected laboratory-based gait and balance measures, and total 
daily-living physical activity are summarized in Figure 1. Total daily-living physical activity was not strongly 
correlated with the scores on any of the MDS-UPDRS tests or with the lab-based assessment of balance or gait. 
Gait speed and MiniBest scores were moderately correlated with MDS-UPDRS-part III scores. 
 
The multivariate associations between each laboratory and daily-living family of metrics and PD motor 
symptom, i.e., MDS-UPDRS-part III, are summarized in Supplementary Material Table 2. Age, sex and disease 
duration explained 6.0%, laboratory-based measures of gait and balance explained 27.1%, and daily-living 
measures explained 37.8% of the variance of the MDS-UPDRS-part III scores.   When considered together in a 
final block-wise regression model, the predictors explained 46.2% of the variance in the MDS-UPDRS-part III 
(see Table 2a). As shown in Figure 2a, daily-living measures accounted for 62.0% of the explained variance, 
laboratory measures for 30.1%, demographics and subject characteristics for 7.7% of the explained variance of 
PD motor symptom severity as assessed in the clinic using the MDS-UPDRS-part III. 
 
Examining these relationships from a different perspective, Supplementary Material Table 3 summarizes the 
contribution of demographics and subject characteristics, MDS-UPDRS (parts I-III) scores and laboratory gait 
and balance measures to the variance in total daily-living physical activity (i.e., SVM). Age, sex and disease 
duration explained 12.4% of the variance, as shown in Model A. Since women had significantly fewer years of 
disease duration and significantly higher SVM, we added a disease duration and sex interaction term to the 
model. As shown in Model B, MDS-UPDRS-part III had the strongest association with total daily-living 
physical activity among the three UPDRS tests, predicting 15.8% of its variance when considered together with 
demographics and subject characteristics. However, the MDS-UPDRS-part III alone accounted for only 5.8%. 
Laboratory-based balance and gait measures explained 27.6% of the SVM variance, as summarized in Model 
C.  
 
When considered together in a final block-wise regression model, 27.1% of the variance of total daily-living 
physical activity was explained (see Table 2b). Laboratory gait simmetry measures accounted for 44.0%, 
demographics and subject characteristics for 42.7%, and the MDS-UPDRS-part III for 13.3% of the  explained 
variance of the total daily-living physical activity (see Figure 2b); in other words, the MDS-UPDRS explained 
less than 4% (0.13 x 0.27=) of the variance in total daily-living physical activity.  Scores on the MDS-UPDRS 
parts I and II were not independently associated with total daily-living physical activity.  
 
 
DISCUSSION 
The results of this cross-sectional analysis indicate that daily-living physical activity, laboratory-based measures 
of dynamic balance, demographics and subject characteristics are related to PD motor symptom severity, as 
expected, and that they explain almost 50% of the variance of motor symptom severity (recall Figure 2a). On 
the flip side, demographics and subject characteristics, laboratory-based gait and balance tests, and disease 
severity (i.e., MDS-UPDRS I-III) explained less than a third of the total daily-living physical activity (recall 
Figure 2b). Taken together, these findings suggest that home-based, 7 days continuous daily-living-based 
measures of mobility and function are related to traditional measures of disease severity, specifically MDS-
UPDRS part III. In addition, daily-living measures also apparently provide additional information that is not 
strongly reflected by conventional standardized, one-time measures conducted in the clinic (e.g., MDS-UPDRS 
I-III, Mini-BESTest).  
 
The contribution of laboratory-based and daily-living physical activity measurements to the variance of PD 
motor symptom severity  
Our results suggest that daily-living mobility monitoring adds considerable explanatory value to the severity of 
motor symptoms in PD. We found that daily-living activity measures independently explain 37.8% of the 
variance of the severity of motor symptoms, as reflected by the MDS-UPDRS-part III (see Supplementary 
Material Table 2). This relatively high value is somewhat surprising when considering that the MDS-UPDRS-
part III score is composed of items that evaluate a wide range of PD non-gait related symptoms including tremor, 
speech, facial expressions, rigidity, and bradykinesia. The MDS-UPDRS-part III items related to gait, balance 
and lower extremity movements account for approximately one-third of the total possible score. This 
demonstrates a noticeable advantage of assessing PD mobility using objective tools of home-based, continuous 
daily function when compared to laboratory-based assessment (mobility capacity) which may be influenced by 
the clinician's subjectivity and the patient's extra effort during a short term examination. Supported by other 
recent studies[19,28], our findings demonstrate the importance of the emerging approach of assessing PD motor 
disability in daily-living conditions based on continuous recordings, in addition to a conventional one-time, 
laboratory assessment. Our analysis revealed important associations between specific measures of daily-living 
activity (daily-living gait variability and the number of longer and shorter walking bouts) and severity of the 
motor symptoms in PD (recall Supplementary Material Table 2). Interestingly, the participants mainly used 
short 5-10 second walking bouts, whereas long bouts (> 120 sec) were rare (recall Supplementary Material 
Table 1). A possible explanation for these findings may be that daily-living activities, mostly at home, were 
composed of a large number of short walking bouts. Perhaps, people with PD with worst disease severity prefer 
to get up for a "good reason" twice a day (the mean of large bouts in our analysis, recall Supplementary Material 
Table 1) instead of making more frequent short movements. Conceivably, improving strength and fitness in 
treatment sessions along with balance training may lengthen PD patients' walking bouts, might positively 
influence their motor disability and even reduce future fall risk.  
The contribution of PD motor symptom severity and other laboratory-based assessment of mobility to the 
variance of total daily-living physical activity 
When trying to explain total daily-living activity, all laboratory tests together (including gait, balance and the 
severity of motor symptom) accounted for less than 30% of its variance (recall Table 2b). These findings, 
supported in part by previous studies[4,28], are likely related to the influence of environmental conditions, 
motor and non-motor fluctuations, comorbidities and other putative mediators of daily-living physical activity 
that cannot be accounted for by one-time laboratory or clinic testing. The best predictors of total daily-living 
activity were demographics and subject characteristics (which were retained in all models), followed by gait 
symmetry measured in the laboratory (see Table 2b). Unexpectedly, balance tests, walking speed and step length 
measured in the lab did not contribute to the variance of the total daily-living physical activity, nor did cognitive 
function (as represented by the Montreal Cognitive Assessment). Somewhat counter-intuitively, we found that 
only the MDS-UPDRS-part III score remained as a predictor (explaining approximately 16% of the variance in 
SVM, together with age, sex and disease duration), while the other two parts of the MDS-UPDRS (ADL and 
non-motor symptoms) did not remain as predictors (see Supplementary Material Table 3). Yet, our results seem 
to be consistent with other research which found that higher age, gender and greater severity of motor symptoms 
are associated with less time spent walking[21] and total energy expenditure (kcal/day)[16]. As previously 
demonstrated, greater total daily-living physical activity is known to protect against a range of diseases and 
negative outcomes [22,23] and is negatively associated with mortality in old age[29]. Moreover, recent studies 
showed that physical activity plays a role in improving a multitude of global and specific motor and non-motor 
symptom in PD patients[17,18]. Thus, in PD, daily physical activity may be considered as a form of non-
pharmacological therapy[17]. Finally, the role of daily-living physical activity as an important predictor of many 
adverse health outcomes suggests that one needs to measure it to gain a more complete estimate of the impact 
of disease and treatments[30]. 
In conclusion, to the best of our knowledge, this is the first systematic examination of the relationship between 
daily-living physical activity and motor symptom severity in patients with PD. On the one hand, our findings 
revealed that standardized measures such as clinic-based MDS-UPDRS-part III along with other laboratory gait 
measures are relatively weak predictors of how patients actually function at home and in the community (i.e., 
outside of the clinic) (recall Table 2b and Figures 1 and 2).  On the other hand, specific daily-living activity 
measures apparently are relatively strong predictors of motor symptom severity (recall Table 2a and Figure 2a). 
These findings emphasize the difference between clinical or laboratory testing and real-life activity of patients. 
Thus, the present results underscore the importance of monitoring daily-living activity for understanding 
disability and disease progression as well as potentially monitoring the effects of interventions and treatments.   
 
Limitations and Future Work 
The present work has several limitations. The cross-sectional nature of this analysis limits our ability to identify 
cause and effect and changes over time. The participants who were analyzed here were all, by definition, fallers. 
In the future, it will be important to see if similar associations are observed among PD subjects who are not 
fallers and among less severely impaired patients. Potential new metrics resulting from more advanced 
analytical approaches (and additional sensing technologies such as gyroscopes) could provide even greater input 
into the functional motor performance of patients during daily-living. Furthermore, it is not possible to fully 
separate passive and active acceleration from the measurement of a tri-axial accelerometer placed on the lower 
back alone.  Nonetheless, the present findings suggest that measuring daily-living physical activity has strong 
potential to more fully and optimally assess patients with PD and to explore functional decline and changes over 
time in response to therapeutic interventions and potential deterioration. Prospective studies are needed to 
further evaluate the degree to which long-term, 24/7 monitoring of gait and physical activity adds new levels of 
granularity and additional relevant information, above and beyond more conventional, one-time assessments. 
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TABLES 
Table 1: Participant characteristics (entries are mean ± SD, median (range) or %). 
 
Table 2a: Multivariable model of joint contributions of lab-based and daily-living measures to the variance in 
motor symptom severity, as evaluated by the MDSUPDRS part III. 
  
Table 2b: Multivariable model of joint contributions of lab-based measures and motor symptom severity to 
the variance in total daily-living physical activity, as measured by the SVM. 
  
FIGURES 
 
Figure 1: Heat map showing the univariate Pearson correlation coefficients between MDS-UPDRS, daily 
living activity, specifically, total daily-living physical activity (SVM), and lab-based measures of gait and 
balance. Darker pixels reflect higher correlation values. Note that MDS-UPDRS parts I-III and total scores are 
only moderately correlated to total daily-living physical activity. Gait speed and the MiniBest were chosen as 
representatives of lab-based representatives because of their widespread use and because of their relatively 
strong association with MDS-UPDRS 3. Similar results were obtained using Spearman’s correlation instead of 
Pearson’s. 
 
 Figure 2: Variance of the two dependent outcome measures. a) Variance in MDS-UPDRS-part III as 
explained by laboratory and daily-living metrics.  Daily-living measures accounted for 62.0%, laboratory 
measures for 30.1% demographics and subject characteristics for 7.7% of the explained variance in the MDS-
UPDRS part III: motor part of the Unified Parkinson's Disease Rating Scale; b) Variance in total physical 
daily-living physical activity, SVM, as explained by subject demographics, the MDS-UPDRS, and laboratory 
measures of gait and balance. Demographics and subject characteristics accounted for 42.7%, MDS-UPDRS-
part III 13.3% and laboratory gait measures for 44.0% proportion of the explained variance.  Note that MDS-
UPDRS parts I and II were included as potential predictors, but they were not significant independent 
predictors and hence were not included in the final model. (MDS-UPDRS part III: motor part of the Unified 
Parkinson's Disease Rating Scale). 
  
Supplementary Material Methods 
 
The use of accelerometer-based technology as a tool for assessing daily-living physical activity 
Physical activity that occurs during daily-living is a modifiable behavior that has numerous known health 
benefits[1,2]. It is not surprising, therefore, that many public health efforts have focused on promoting a more 
active lifestyle to improve the health of older adults and patients with disease[3]. Traditionally, community-
based studies used self-report and questionnaires to assess physical activity[4]. More recently, with the advance 
of technology, activity monitoring (also referred to by some as actigraphy) has been used to quantify daily-
living activity. Activity monitoring is a non-invasive method that is widely used in epidemiologic and other 
studies to objectively measure how active (or inactive and sedentary) an individual is. With activity monitoring, 
an unobtrusive, body-fixed sensor captures movement continuously over the course of several days using a 
small accelerometer to measure total daily-living physical activity;  this approach mitigates the problems of 
self-report like recall bias and other sources of subjectivity[5]. Previous work using an accelerometers to 
measure activity has shown that measures of total daily-living physical activity are related to and predictive of 
many important health outcomes such as obesity, death[6,7], disability[8,9], cognitive decline[10], mild 
cognitive impairment[11,12], and dementia[10,13,14]. Moreover, recent studies showed that physical activity 
plays a role in improving a multitude of global and specific motor and non-motor symptom in patients with 
Parkinson's disease[15,16]. 
 
Typically, a small sensor is worn for a week or more to measure gross motor activity. Older activity monitoring 
sensors that were based on an accelerometer stored and reported activity counts as measured in 15 second 
windows and then summed the results over days or a week. Newer devices measure and record the acceleration 
(and hence movement) in 3 dimensions and can be also be used to quantify total daily-living physical activity 
as well as gait quantity and quality, as done in the present study. To obtain the amount of physical activity, the 
movement in all three acceleration axes are accounted for by determining the signal vector magnitude, SVM, 
essentially, the sum of the acceleration signal across each of the 3 orthogonal directions (vertical, v, aneterior-
posterior, ap, and medial-lateral, ml) , at every sample point:  
𝑆𝑉𝑀 = √𝑎𝑐𝑐𝑣
2 + 𝑎𝑐𝑐𝑎𝑝
2 +𝑎𝑐𝑐𝑚𝑙
2  
 
Once the SVM is determined at each time point, it can be summed over 15-second blocks and then summed 
over the day to produce actigraphy-like measures of daily-living. In the present analyses, SVM refers to the 
total daily-living physical activity as the activity measure is summed over the day (and averaged over each day 
of the recording).  In addition, the raw acceleration can be used to quantify gait and other movement features.  
 
Daily-living physical activity may be influenced by factors such as exercise, cognition, affect, and social 
interactions. Therefore, objective monitoring putatively captures activity features that are not reflected in a 
single test in a laboratory or by self-report questionnaires. Due to developments in the technology, 
accelerometers and related devices have become one of the most widely used method for objective assessment 
of physical activity in large scale studies[17-21].  For example, the recent UK Biobank study assessed daily-
living activity in more than 10,000 subjects using an accelerometer (the same one used in the present study)[22] 
and NIH-sponsored study of mobility in older adults also used a similar device[23].  
 
The selection of the wearable device and its location 
The Axivity 3-D accelerometer sensor used in the present work has been used as the basis for assessing activity 
in more than 150 publications. It is the same device that is used in the large UK Biobank study and is very 
similar to other devices used to measure daily-living activity[24-28], using the same principles and concepts 
applied in the present analyses.  In order to evaluate ‘whole body’ movement, we choose to place the 
accelerometer close to the center of mass, as previously described by Mathie et al. [29] and used in other studies 
[30-33] (among many others).  
 
  
  
 
Supplementary Material Figure 1. Block diagram summarizing the analysis process  
  
Supplementary Material Table 1: Daily-living and laboratory based measures 
 Variable Mean ± SD 
Laboratory functional and performance based variables  
Balance & Functional 
Tests 
Mini-Balance Evaluation 
Systems Tests (Mini-BESTest) 
21.48±5.38 
Four Square Step Test (FSST) 13.40±5.51 
Gait Quantity Two Minute Walk Distance [m] 
(2MinWalk) 
123±30 
Gait Pace Step length [cm] 
(GMstepLength) 
55.42±11.25 
 
Gait Rhythm Cadence [steps/min] 110.91±11.77 
Gait Symmetry Step symmetry V axis [unitless] 
(StpSymV) 
 
0.99±0.20 
 
Step regularity V axis [unitless] 
(StpRegV) 
0.58±0.15 
Harmonic ratio V Axis [unitless] 
(HRv) 
0.86±0.18 
Harmonic ratio ML Axis 
[unitless] (HRml) 
0.63±0.16 
Gait Variability Stride regularity V axis [unitless] 
(StrRegV) 
 
0.59±0.14 
 
Dominant frequency V axis [Hz] 
(FrqV) 
1.82±0.18 
Daily-living based variables* 
Activity Sum SVM at day time [g] 
( SVMDay) 
1844±701 
Percent Active at Night [%] 
( PrcActiveNight)  
2.99±1.86 
  
 
 
 
 
 
Sleep Mean nap bout at day time 
[minutes] 
(MeanNapBout)  
 
43.05±28.55 
Gait Quantity Number of walking bouts 5-10 
sec [#] 
98.52±48.73 
Number of walking bouts >120 
sec [#] 
2.30±2.35 
Gait Pace Mean step length [cm] 
(MeanStepLength) 
54.48±7.87 
Gait Symmetry Step regularity ML axis [unitless] 
(stpRegML) 
0.28±0.10 
Gait Variability Dominant frequency ML axis 
[Hz]  
(frqML) 
0.90±0.09 
Amplitude of the dominant 
frequency ML axis [g2/Hz] 
(ampML) 
0.28±0.14 
SD across walking bouts SD of step length [cm] 
(SD_StepLength)  
4.12±2.11 
SD of the peaks amplitude CV 
[g2/Hz]  
(SD_CVAMPPeaks) 
0.14±0.06 
SD of width of the dominant 
frequency ML axis [Hz] 
(SD_wdML) 
0.16±0.11 
SD cadence of V axis [Hz] 
(SD_Cadence)   
                5.18±2.15 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*In the case of daily-living measures, only those that remained significant in each sub-category after the 
backwards elimination process are presented here. 
Supplementary Material Table 1: Contributions of lab-based and daily-living based measures to 
the variance in the severity of motor symptoms (MDS-UPDRS Part III) 
Models  R2 
Model A – 
Demographics 
and Subject 
Characteristics   
Age  (β=.215)* 0.060 
 Sex  (β=0.140) 
Disease Duration  (β=.174)* 
Model B – 
Laboratory 
Gait and 
Balance 
Measures 
Sub-category Predictors within each sub-category R2  
Balance 
&Functional tests**  
Mini-BESTest (β=-0.532)* 0.283 
0.271 
 
Gait Quantity 2MinWalk (β=-0.408) 0.179 
Gait Pace GMstepLength  (β=-0.351) 0.193 
Gait Symmetry StepSymV (β=0.223) 0.140 
Gait Variability StrRegV (β=-0.224) 0.124 
 Demographics   (β=NS)   
Model C – 
Daily-Living 
Measures 
Sub-category Predictors within each sub-category 
 
R2 0.378 
 Activity PrcActiveNight (β=-0.163) 
SVMDay (β=-0.222)  
 
0.114 
Sleep MeanNapBout (β=0.182) 0.033 
Gait Quantity** Number of Walking bouts 5-10 sec  
(β=-0.451)*                          
Number of Walking  bouts >120 
sec  (β=0.261)* 
0.228 
Gait Pace MeanStepLength  (β=-0.314) 0.099 
Gait Symmetry StpRegML (β=0.189)* 0.092 
Gait Variability** frqML (β=0.355)* 
ampML (β=0.355)* 
 
0.264 
SD across walking 
bouts 
STD_StepLength  
(β=-0.165)*                              
STD_wdML (β=-0.263)* 
STD_Cadence (β=-0.157)* 
STD_CVAMPPeaks (β=0.198)* 
0.224 
 Demographics   (β=NS)   
* Features that remained following backwards regression within each category. 
** Categories remained in the final backwards regression with both laboratory gait and balance and daily-living 
measures. 
β=NS: This feature did not survive following backwards regression within its subcategory. 
 
Supplementary Material Table 3: Contributions of Lab-based Measures, UPDRS-part I-III to 
Variance in total daily-living physical activity as measured by the SVM 
Models  R2 
Model A - 
Demographics and 
Subject 
Characteristics!   
Age (β=-0.208)* 0.124 
 Sex (β=-0.053)* 
Disease Duration  (β=-0.219)* 
Sex-Disease Duration interaction  (β=0.455)* 
Model B – Disease 
Severity Scores 
 
UPDRS part I (β=NS) 0.158 
UPDRS part II (β=NS) 
UPDRS  part III  (β=-0.286)* 
Demographics  (β=0.499)* 
Model C – 
Laboratory Gait 
and Balance 
Measures 
 R2 0.276 
 Function 
Performance 
Based Balance 
Measurements 
FSST (β=NS) 
Mini-BESTest 
(β=0.215)* 
Sex (β=0.222)  
Disease Duration        
(β=-0.212) 
Age (β=-0.217) 
Sex-Disease Duration 
interaction  (β=0.461)* 
0.205 
Gait Quantity 2MinWalk  (β=0.377)* 
Sex (β=0.222) 
Disease Duration 
(β=-0.192) 
0.212 
Gait Rhythm Cadence* (β=0.170)  
Sex (β=0.187)  
Disease Duration 
(β=0.178)  
Age (β=-0.157) 
StrideTimeV (β=NS) 
0.139 
 
Gait 
Symmetry** 
HRv (β=-0.192) * 
StpSymV (β=NS)        
StpRegV (β=0.297)*            
HRml (β=0.170)*                 
Sex (β=0.233)       
Disease Duration 
(β=0.233)                    
Age (β=-0.178) 
0.273 
Gait Variability StrRegV (β=0.387)* 
FrqV (β=NS)                         
Sex-Disease Duration 
interaction (β=0.314) 
0.236 
*Features remained following backwards regression within subcategory. 
** Categories remained in the final backwards regression.   
!MoCA score as a representor of cognitive abilities was included as potential predictor in this model but did not remain 
after backwards elimination. 
β=NS: This feature did not survive following backwards regression within this subcategory. 
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The use of accelerometer-based technology as a tool for assessing daily-living physical activity 
Physical activity that occurs during daily-living is a modifiable behavior that has numerous known health 
benefits[1,2]. It is not surprising, therefore, that many public health efforts have focused on promoting a more 
active lifestyle to improve the health of older adults and patients with disease[3]. Traditionally, community-
based studies used self-report and questionnaires to assess physical activity[4]. More recently, with the advance 
of technology, activity monitoring (also referred to by some as actigraphy) has been used to quantify daily-
living activity. Activity monitoring is a non-invasive method that is widely used in epidemiologic and other 
studies to objectively measure how active (or inactive and sedentary) an individual is. With activity monitoring, 
an unobtrusive, body-fixed sensor captures movement continuously over the course of several days using a 
small accelerometer to measure total daily-living physical activity;  this approach mitigates the problems of 
self-report like recall bias and other sources of subjectivity[5]. Previous work using an accelerometers to 
measure activity has shown that measures of total daily-living physical activity are related to and predictive of 
many important health outcomes such as obesity, death[6,7], disability[8,9], cognitive decline[10], mild 
cognitive impairment[11,12], and dementia[10,13,14]. Moreover, recent studies showed that physical activity 
plays a role in improving a multitude of global and specific motor and non-motor symptom in patients with 
Parkinson's disease[15,16]. 
 
Typically, a small sensor is worn for a week or more to measure gross motor activity. Older activity monitoring 
sensors that were based on an accelerometer stored and reported activity counts as measured in 15 second 
windows and then summed the results over days or a week. Newer devices measure and record the acceleration 
(and hence movement) in 3 dimensions and can be also be used to quantify total daily-living physical activity 
as well as gait quantity and quality, as done in the present study. To obtain the amount of physical activity, the 
movement in all three acceleration axes are accounted for by determining the signal vector magnitude, SVM, 
essentially, the sum of the acceleration signal across each of the 3 orthogonal directions (vertical, v, aneterior-
posterior, ap, and medial-lateral, ml) , at every sample point:  
𝑆𝑉𝑀 = √𝑎𝑐𝑐𝑣
2 + 𝑎𝑐𝑐𝑎𝑝
2 +𝑎𝑐𝑐𝑚𝑙
2  
 
Once the SVM is determined at each time point, it can be summed over 15-second blocks and then summed 
over the day to produce actigraphy-like measures of daily-living. In the present analyses, SVM refers to the 
total daily-living physical activity as the activity measure is summed over the day (and averaged over each day 
of the recording).  In addition, the raw acceleration can be used to quantify gait and other movement features.  
 
Daily-living physical activity may be influenced by factors such as exercise, cognition, affect, and social 
interactions. Therefore, objective monitoring putatively captures activity features that are not reflected in a 
single test in a laboratory or by self-report questionnaires. Due to developments in the technology, 
accelerometers and related devices have become one of the most widely used method for objective assessment 
of physical activity in large scale studies[17-21].  For example, the recent UK Biobank study assessed daily-
living activity in more than 10,000 subjects using an accelerometer (the same one used in the present study)[22] 
and NIH-sponsored study of mobility in older adults also used a similar device[23].  
 
The selection of the wearable device and its location 
The Axivity 3-D accelerometer sensor used in the present work has been used as the basis for assessing activity 
in more than 150 publications. It is the same device that is used in the large UK Biobank study and is very 
similar to other devices used to measure daily-living activity[24-28], using the same principles and concepts 
applied in the present analyses.  In order to evaluate ‘whole body’ movement, we choose to place the 
accelerometer close to the center of mass, as previously described by Mathie et al. [29] and used in other studies 
[30-33] (among many others).  
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Supplementary Material Table 1: Daily-living and laboratory based measures 
 Variable Mean ± SD 
Laboratory functional and performance based variables  
Balance & Functional 
Tests 
Mini-Balance Evaluation 
Systems Tests (Mini-BESTest) 
21.48±5.38 
Four Square Step Test (FSST) 13.40±5.51 
Gait Quantity Two Minute Walk Distance [m] 
(2MinWalk) 
123±30 
Gait Pace Step length [cm] 
(GMstepLength) 
55.42±11.25 
 
Gait Rhythm Cadence [steps/min] 110.91±11.77 
Gait Symmetry Step symmetry V axis [unitless] 
(StpSymV) 
 
0.99±0.20 
 
Step regularity V axis [unitless] 
(StpRegV) 
0.58±0.15 
Harmonic ratio V Axis [unitless] 
(HRv) 
0.86±0.18 
Harmonic ratio ML Axis 
[unitless] (HRml) 
0.63±0.16 
Gait Variability Stride regularity V axis [unitless] 
(StrRegV) 
 
0.59±0.14 
 
Dominant frequency V axis [Hz] 
(FrqV) 
1.82±0.18 
Daily-living based variables* 
Activity Sum SVM at day time [g] 
( SVMDay) 
1844±701 
Percent Active at Night [%] 
( PrcActiveNight)  
2.99±1.86 
*In the case of daily-living measures, only those that remained significant in each sub-category after the 
backwards elimination process are presented here. 
Sleep Mean nap bout at day time 
[minutes] 
(MeanNapBout)  
 
43.05±28.55 
Gait Quantity Number of walking bouts 5-10 
sec [#] 
98.52±48.73 
Number of walking bouts >120 
sec [#] 
2.30±2.35 
Gait Pace Mean step length [cm] 
(MeanStepLength) 
54.48±7.87 
Gait Symmetry Step regularity ML axis [unitless] 
(stpRegML) 
0.28±0.10 
Gait Variability Dominant frequency ML axis 
[Hz]  
(frqML) 
0.90±0.09 
Amplitude of the dominant 
frequency ML axis [g2/Hz] 
(ampML) 
0.28±0.14 
SD across walking bouts SD of step length [cm] 
(SD_StepLength)  
4.12±2.11 
SD of the peaks amplitude CV 
[g2/Hz]  
(SD_CVAMPPeaks) 
0.14±0.06 
SD of width of the dominant 
frequency ML axis [Hz] 
(SD_wdML) 
0.16±0.11 
SD cadence of V axis [Hz] 
(SD_Cadence)   
                5.18±2.15 
Supplementary Material Table 2: Contributions of lab-based and daily-living based measures to 
the variance in the severity of motor symptoms (MDS-UPDRS Part III) 
Models  R2 
Model A – 
Demographics 
and Subject 
Characteristics   
Age  (β=.215)* 0.060 
 Sex  (β=0.140) 
Disease Duration  (β=.174)* 
Model B – 
Laboratory 
Gait and 
Balance 
Measures 
Sub-category Predictors within each sub-category R2  
Balance 
&Functional tests**  
Mini-BESTest (β=-0.532)* 0.283 
0.271 
 
Gait Quantity 2MinWalk (β=-0.408) 0.179 
Gait Pace GMstepLength  (β=-0.351) 0.193 
Gait Symmetry StepSymV (β=0.223) 0.140 
Gait Variability StrRegV (β=-0.224) 0.124 
 Demographics   (β=NS)   
Model C – 
Daily-Living 
Measures 
Sub-category Predictors within each sub-category 
 
R2 0.378 
 Activity PrcActiveNight (β=-0.163) 
SVMDay (β=-0.222)  
 
0.114 
Sleep MeanNapBout (β=0.182) 0.033 
Gait Quantity** Number of Walking bouts 5-10 sec  
(β=-0.451)*                          
Number of Walking  bouts >120 
sec  (β=0.261)* 
0.228 
Gait Pace MeanStepLength  (β=-0.314) 0.099 
Gait Symmetry StpRegML (β=0.189)* 0.092 
Gait Variability** frqML (β=0.355)* 
ampML (β=0.355)* 
 
0.264 
SD across walking 
bouts 
STD_StepLength  
(β=-0.165)*                              
STD_wdML (β=-0.263)* 
STD_Cadence (β=-0.157)* 
STD_CVAMPPeaks (β=0.198)* 
0.224 
 Demographics   (β=NS)   
* Features that remained following backwards regression within each category. 
** Categories remained in the final backwards regression with both laboratory gait and balance and daily-living 
measures. 
β=NS: This feature did not survive following backwards regression within its subcategory. 
 
Supplementary Material Table 3: Contributions of Lab-based Measures, UPDRS-part I-III to 
Variance in total daily-living physical activity as measured by the SVM 
Models  R2 
Model A - 
Demographics and 
Subject 
Characteristics!   
Age (β=-0.208)* 0.124 
 Sex (β=-0.053)* 
Disease Duration  (β=-0.219)* 
Sex-Disease Duration interaction  (β=0.455)* 
Model B – Disease 
Severity Scores 
 
UPDRS part I (β=NS) 0.158 
UPDRS part II (β=NS) 
UPDRS  part III  (β=-0.286)* 
Demographics  (β=0.499)* 
Model C – 
Laboratory Gait 
and Balance 
Measures 
 R2 0.276 
 Function 
Performance 
Based Balance 
Measurements 
FSST (β=NS) 
Mini-BESTest 
(β=0.215)* 
Sex (β=0.222)  
Disease Duration        
(β=-0.212) 
Age (β=-0.217) 
Sex-Disease Duration 
interaction  (β=0.461)* 
0.205 
Gait Quantity 2MinWalk  (β=0.377)* 
Sex (β=0.222) 
Disease Duration 
(β=-0.192) 
0.212 
Gait Rhythm Cadence* (β=0.170)  
Sex (β=0.187)  
Disease Duration 
(β=0.178)  
Age (β=-0.157) 
StrideTimeV (β=NS) 
0.139 
 
Gait 
Symmetry** 
HRv (β=-0.192) * 
StpSymV (β=NS)        
StpRegV (β=0.297)*            
HRml (β=0.170)*                 
Sex (β=0.233)       
Disease Duration 
(β=0.233)                    
Age (β=-0.178) 
0.273 
Gait Variability StrRegV (β=0.387)* 
FrqV (β=NS)                         
Sex-Disease Duration 
interaction (β=0.314) 
0.236 
*Features remained following backwards regression within subcategory. 
** Categories remained in the final backwards regression.   
!MoCA score as a representor of cognitive abilities was included as potential predictor in this model but did not remain 
after backwards elimination. 
β=NS: This feature did not survive following backwards regression within this subcategory. 
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